Diamedica Therapeutics Inc. · NASDAQ:DMAC
Diamedica Therapeutics — Investor Presentation (June 2023)
26 slides from Diamedica Therapeutics's investor presentation, Jun 21, 2023
Slide 1: Corporate Presentation June 2023
AS THERAPEUTICS Corporate Presentation June 2023
Slide 2: Cautionary Note Regarding Forward-Looking Statements
Cautionary Note Regarding Forward-Looking Statements us. “estimate, “believe,” “anticipate” “intend “expect, "plan, “continue,” “potential "wil" “may” or “shoul,” the negative ofthese words o such variations achievements, OM: data may fale its M199) stro 199; A193 ic i , ite ing "Rsk Factors i Decem
Slide 3: Company Overview
Company Overview >$10 Billion US Market Opportunity for Acute Ischemic Stroke (AIS) + >80% of patients have no treatment option today = Nonew approved therapeutics in over 25 years Lead Program: DM199 - Novel, Late-Stage Biologic Therapy ‘+ Recombinant KLK1 protein with FDA Fast-Track Designation =
Slide 4: Recent Developments
Recent Developments Significantly in the last 18 months Strengthened = Vicor Senior Leadership ‘0. New Chief Medical Officer, Chief Commercial Officer, PHARMA Pfizer Tn Chie! Buses Ofer and end of Cea Operations. Qeyse. Genentech + 30f i join "i at | Significantly DiaMedica in the last 18 months — F
Slide 5: DiaMedica Pipeline
DiaMedica Pipeline Current Focus is on AIS Pivotal Study Program Product | Prectncl Pivotal SEE net as ot) OMI? francine {OAc ie ne 2023 Beam Sub-Study: Stroke Recurrence wise {FDA Fast Tack Designation BoE Planned tobe Discoseain2H 2023 oMi99 ea ‘Tobe diclosedindcaton in Caden g2 3° ‘Ongoing develo
Slide 6: High Unmet Need in Acute Ischemic Stroke
High Unmet Need in Acute Ischemic Stroke >7.5 Million Acute Ischemic Strokes Globally®: ~80% of Patients Have No Treatment Options Low Treatment Rates Limited Treatment Options US Annual Acute Ischemic Strokes!23 —! a ine>+ >500k with no treatment option tPA/ Mechanical Supportive ‘Thrombolytic Thro
Slide 7: DM199 Initial Target in AIS - Significant Whitespace Opportunity
DM199 Initial Target in AIS - Significant Whitespace Opportunity >500K Patients in the US with No Treatment Option + The 4.s+ + 92% of, in 24 hours 9-12hours | 12-24 hours Stroke Type CpDaMedica
Slide 8: Low KLK1 Levels Associated With AIS Incidence & Poor Outcomes
Low KLK1 Levels A i With AIS Inci & Poor O1 DM199 Pharmacological Approach is to Increase KLK1 Levels to Treat & Prevent Recurrent Stroke Low KLK1 Levels Independently Associated with [fM AIS Patients with Unfavorable Outcomes & Death First Stroke and Predictor of Recurrent Stroke Had 80% Lower KLK1
Slide 9: Human Urinary KLK1 (HUK): Safe and Efficacious Treatment For AIS
Human Urinary KLK1 (HUK): Safe and Efficacious Treatment For AIS Standard of Care in China: >600k AIS patients Treated in 2022 @Rirow, + HUK for Als: = ee Marketed by Shanghai Pharmaceuticals under Kailkang®. Efficacy and safety of human ee i : i urinary for ieee acute ischemic stroke: , ‘nchi : lys
Slide 10: DM199 Novel Mechanism of Action (MOA)
DM199 Novel Mechanism of Action (MOA) Local Vasodilation in Stroke and Other Vascular Diseases FE ee eonein + Ly Sasi ao metabozed by angtesn converting enrme + KLK1 is made predominately in kidneys (present also in the ‘vasculature and brain) and circulates in the bloo 1DM199 (recombinant KLK1) act
Slide 11: Activation of Bradykinin 2 (BK2) Receptors
‘ion of inin2 (BK2) S Ischemia Naturally Induces Upr 1) The BK2 receptor plays a critical role in regulating vascular tone and blood pressure under normal conditions. tissues, including the brain.* @ hrresponse to ischemic conditions, the BK2 receptors receptors in the affected arteries es , © M199
Slide 12: DM199 MOA: Improve Collateral Circulation in Acute Ischemic Stroke
DM199 MOA: Improve Collateral Circulation in Acute Ischemic Stroke Novel Mechanism With Potential to Improve Stroke Outcomes & Reduce Risk of Stroke Recurrence No DM199 treatment DM199 treatment therapeutic benefit. DM199 facilitates release of endothelial nitric oxide and prostaglandins to selectiv
Slide 13: Human Urinary KLK1 (HUK) Improved Cerebral Blood Flow and Patient Outcomes
Human Urinary KLK1 (HUK) Improved Cerebral Blood Flow and Patient Outcomes % Change in MTT Proportion of mRS 0-2 (Day 12 vs. Baseline) (at 90 Days) 26 5 g 30.1% $2 3 10% . maze as g _ g & 8 2 s ® g Placebo Placebo No2e Nae Improved relative MTT associated with favorable functional outcome OR=0.483 9
Slide 14: DM199 P2 AIS Study: Outcomes Improved In Sub-Group Excluding MT
DM199 P2 AIS Study: Outcomes Improved In Sub-Group Excluding MT Population More Closely Aligns with Ongoing Pivotal P2/3 Study and HUK Use in China Days* nt Outcom 40% Placebo (N=21) Ma99 (N-25) asx 360% a % of Patients at Day 90 15% 10% 140% 5% 5.0% 0% NIHSS <1 mRS <1; NIHSS <1; BI>95 Relative Incr
Slide 15: DM199 P2 Study Shows Potential for Best-in-Class Improvement in AIS Outcomes
DM199 P2 Study Shows Potential for Best-in-Class Improvement in AIS Outcomes DM199 Exceeded Clinical Efficacy Bar Established By tPA With 24-Hour Treatment Window ce ‘% of ‘Stand mRS <' (M199 Analysis Excludes MT Treated Patients) ‘+ tPA (Activase®) approved in 19% for AIS © Short 45-hour treatment
Slide 16: DM199 P2 AIS Study: Recurrence & Death Reduced In Sub-Group Excluding MT
DM199 P2 AIS Study: Recurrence & Death Reduced In Sub-Group Excluding MT Population More Closely Aligns with Ongoing Pivotal P2/3 Study and Use of HUK in China 25% Placebo (N=21) 24.0% Bi om199 1-25) -0.037 Sof Patients at Day 90 Relative Decrease -100% -50% Absolute Decrease 19% 12% §diaMedica
Slide 17: ReMEDy2 DM199 P2/3 AIS Study Adaptations Based on Phase 2 Findings
9% % .sReMEDy2 DM199 P2/3 AIS Study Adaptations Based on Phase 2 Findings Aligning Study Population To Best Efficacy Signal Observed In Phase 2 & HUK-Treated Population Observations and Rationale + Genentech's PS © Greater DM19 + 42%of ite hig placebo Lowered NIHSS baseline inclusion range from 6-25
Slide 18: ReMEDy2 DM199 Pivotal P2/3 Study Design
€ Ne % “éReMEDy2 DM199 Pivotal P2/3 Study Design With Interim Analysis to Manage Statistical Powering Key Eligibility Criteria += Mild to Moderate AIS: NIHSS: 3-20 * AIS confirmed via a? «N= -340 patients = Interim analysis @ 140 jon Cr + Hemorrhagic stroke + Large vessel occlusion stroke (Aspe crin
Slide 19: Corporate Summary
Corporate Summary DiaMedica
Slide 20: DM199 Multi-layered IP Position and Potential for Regulatory Exclusivity
DM199 Multi-layered IP Position and Potential for Regulatory Exclusivity Key manufacturing challenges solved: protein activity, stability and economical scale Basents endiicede Secrets DiaMedica overcame challenges in Gee tion of = Commercial scale recombinant KLK1 protein + Composition of matter Pe
Slide 21: Leadership and Board of Directors
Quintiles. President Leadership Board of Directors Rick Pauls Richard Pin President & CEO Chairman of the Board c ' Fe Jud Scott Kellen, Michael Giutfre, M.D. Chief Financial Officer 25+ years in lie sciences industry. CPA (inactive), held senior leadership roles Kirsten Gruis, M.D. ‘Chief Medical O
Slide 22: Summary
Summary >$10 Billion US Market Opportunity for Acute Ischemic Stroke (AIS) + >80% of patients have no treatment option today = Nonew approved therapeutics in over 25 years Lead Program: DM199 - Novel, Late-Stage Biologic Therapy ‘+ Recombinant KLK1 protein with FDA Fast-Track Designation the No bloo
Slide 23: Thank you!
s”Z DiaMedica TS THERAPEUTICS NASDAQ: DMAC iv www.diamedica.com Thank you!
Slide 24: Appendix
| Al Wy nS W\\ is taMedica Appendix THERAPEUTICS
Slide 25: Modified Rankin Scale (mRS) Assesses the Level of Disability
Modified Rankin Scale (mRS) Assesses the Level of Disability by = ReMEDy2 Primary endpoint Rok 4% ‘own body needs §diaMedica Low disablity ~ Moderate disability Severe disability ft patent
Slide 26: Human Urinary KLK1 (HUK) Increased Collateral Blood Flow After Stroke
Human Urinary KLK1 (HUK) Increased Collateral Blood Flow After Stroke Treatment INCREASED INCREASED VESSELS BLoop Flow imaging findi HUK/KLK1, via focal arterial vasodilatio “collateral blood flow sp n, can increase ically to the area of brain affected by an acute ischemic stroke FPraMedica — pas et
DiaMedica Therapeutics — Investor Presentation (June 2023) on 6ix